Rapport Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$25.91

+1.85%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: $26.12
Previous close: $25.44
Volume: 956,868
Day's high: $26.36
Day's low: $25.27

In brief

Rapport Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.46B.
Its shares closed at $25.93 on 4 Nov 2026, down 2.7% over the past year.
From India you can buy RAPP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Rapport Therapeutics, Inc. (RAPP) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RAPP share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RAPP options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −16.8% (SPY −1.6%, XLV +13.5%). 3 months: −38.9% (SPY −0.4%, XLV +15.5%). 1 year: −2.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RAPP, SPY and XLV · as of 4 Nov 2026
11.8 days to cover short interest
3.1M shares were sold short at the 15 Oct 2026 settlement, 6.4% of the 48.0M shares outstanding; covering them would take 11.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $25.93 was 26.5% below its 50-day average ($35.26) and 27.2% below its 200-day average ($35.63). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
17.5% above its 52-week low
Closed at $25.93 on 4 Nov 2026: 51.0% below the 52-week high of $52.93 (27 Aug 2026) and 17.5% above the low of $22.06 (28 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 3.0× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 3.1M shares was 3.0× the average of the 30 sessions before it (1.0M), as the price rose 7.6%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.8%

6 months−30.0%

1 year−2.7%

5 years—

Newswire

About

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Website

Notable moves

September 8, 2025
+119.15%
June 3, 2025
+30.21%
March 4, 2025
+39.72%

Newswire

About

Website

Notable moves

September 8, 2025
+119.15%
June 3, 2025
+30.21%
March 4, 2025
+39.72%

Rapport Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$25.91

+1.85%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: $26.12
Previous close: $25.44
Volume: 956,868
Day's high: $26.36
Day's low: $25.27

In brief

Rapport Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.46B.
Its shares closed at $25.93 on 4 Nov 2026, down 2.7% over the past year.
From India you can buy RAPP in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Rapport Therapeutics, Inc. (RAPP) shares from India?

Do I need the price of a whole RAPP share to invest?

How much can I invest in US stocks in a year?

Can I trade RAPP options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −16.8% (SPY −1.6%, XLV +13.5%). 3 months: −38.9% (SPY −0.4%, XLV +15.5%). 1 year: −2.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RAPP, SPY and XLV · as of 4 Nov 2026
11.8 days to cover short interest
3.1M shares were sold short at the 15 Oct 2026 settlement, 6.4% of the 48.0M shares outstanding; covering them would take 11.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $25.93 was 26.5% below its 50-day average ($35.26) and 27.2% below its 200-day average ($35.63). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
17.5% above its 52-week low
Closed at $25.93 on 4 Nov 2026: 51.0% below the 52-week high of $52.93 (27 Aug 2026) and 17.5% above the low of $22.06 (28 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 3.0× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 3.1M shares was 3.0× the average of the 30 sessions before it (1.0M), as the price rose 7.6%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.8%

6 months−30.0%

1 year−2.7%

5 years—

Newswire

About

Website

Notable moves

September 8, 2025
+119.15%
June 3, 2025
+30.21%
March 4, 2025
+39.72%

Newswire

About

Website

Notable moves

September 8, 2025
+119.15%
June 3, 2025
+30.21%
March 4, 2025
+39.72%

Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.8 days to cover short interest

Below its 50- and 200-day averages

17.5% above its 52-week low

Volume 3.0× its 30-session average on 29 Oct 2026

Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.8 days to cover short interest

Below its 50- and 200-day averages

17.5% above its 52-week low

Volume 3.0× its 30-session average on 29 Oct 2026